Sanofi SA (ADR) (SNY)’s GLP-1 Accepted for Review by FDA

The combo could come up against Novo’s pipeline combination of Victoza with the insulin Tresiba. But the FDA recently refused Tresiba, which was already approved in Europe, and requested further testing for cardiovascular safety.

Foolish final thoughts
Watch to make sure that solo lixisenatide makes it past the FDA, but then turn your attention to the combo trials. That could become lixisenatide’s place in the market — especially if Tresiba keeps running into problems.

The article Sanofi’s GLP-1 Accepted for Review by FDA originally appeared on Fool.com and is written by Brandy Betz.

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.